blank student in laboratory
Important Information
UA System Patent Policy
UAB Conflicts of Interest Policy
UAB Conflicts of Commitment Policy

The UAB-Wyeth Licensing Agreement Has Long-Term Goals

In December 1999, The UAB Research Foundation (UABRF) and Wyeth signed an exclusive license agreement for the development of vaccines against certain viral diseases using vesicular stomatitis virus (VSV) as a vector for vaccine delivery. This license agreement granted Wyeth exclusive rights to a large body of technology that had been created at the University of Alabama at Birmingham (UAB).

Over the past nine years, Wyeth has been developing this technology in accordance with the terms of its exclusive license agreement. UABRF and Wyeth also have cooperated to ensure that the associated intellectual property is protected.

From Concept to Commercialization

The UAB Research Foundation (UABRF), a nonprofit 501(c)3 corporation, is the designated intellectual property management organization for the University of Alabama at Birmingham (UAB). Intellectual property can generate monetary value and benefit the public good when it is used to develop products and services. It is the responsibility of UABRF to identify, protect, market to commercial entities, and license intellectual property that is developed by UAB faculty members, employees, and graduate students.

UAB’s Toolbox for Pneumococcal Diseases

The World Health Organization estimates that Streptococcus pneumoniae kills one million children under the age of five annually. Millions of people worldwide suffer from pneumonia caused by S. pneumoniae, and similar numbers develop less serious conditions such as otitis media (infection in the middle ear). Currently available vaccines can protect only against the most common S. pneumoniae serotypes (strains), and infections still occur because not all S. pneumoniae serotypes are present in these vaccines.